Switzerland's Medicines for Malaria Receives Gates Foundation Award
19 October
Medicines for Malaria Venture (MMV, Geneva, Switzerland) - a not-for-profit public-private partnership- has received its fifth and largest grant from the Bill & Melinda Gates Foundation. The grant will fund MMV's R&D pipeline to the tune of an additional $115 million over the next 5 years. The award brings the venture's cumulative funding - from government agencies, private foundations, international organizations, and corporate foundations - to $470 million.
MMV employs the whole gamut of drugs and healthcare devices in its plight to eradicate malaria, from vaccines and diagnostics to insecticide-treated bed-nets.
Dr Timothy Wells, MMV’s CSO commented on the Gates award: “This funding arrives at a critical time for us. Over the last few months, with our partners we have launched a high-quality antimalarial designed specially for children (Coartem Dispersible), submitted another antimalarial to the EMEA for regulatory approval (Eurartesim), and are in the process of collating the regulatory dossier for a third antimalarial (Pyramax). [But] with the emergence of resistance to Artemisinin in Cambodia, it’s clear that the ambitious goal of malaria eradication will require a wide range of new medicines."
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
